Prospective Evaluation of the Peptide-Bound Collagen Type I Cross-Links N-Telopeptide and C-Telopeptide in Predicting Bone Metastases Status

Costa, Luís; Demers, Laurence M.; Oliveira, António G.; Schaller, Jill; Costa, Eduardo B.; Moura, Miguel Carneiro de; Lipton, Allan

doi:10.1200/jco.20.3.850

Cited by 137 publications

(109 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…67 More recently, denosumab was compared with ZA in patients with BM from several types of solid tumors and multiple myeloma; 1,68,69 in these studies, denosumab was more effective delaying time to first and subsequent SRE, which was correlated with a greater control of bone turnover marker levels (NTX-I and BALP). 1,68 Costa et al 12 further studied the role of bone markers in the diagnosis of disease progression. In this prospective cohort study, the authors tested 3 bone markers (NTX-I, ICTP and BALP) in 123 patients with various metastatic cancers, 26 of which were extraosseous only (45 bone-only and 52 bone plus visceral).…”

Section: Prediction Of Patients' Outcomesmentioning

confidence: 99%

“…71 Moreover, the rate of adverse events associated with BP treatment increases with time, 71 and only limited evidence assessed long-term use of BPs. 12,71 Given the prompt response of bone markers to treatment with BTAs and their use as predictors of BTAs efficacy (particularly with ZA), some authors hypothesized that the serial measurement of bone markers could be a strategy to tailor therapy regimen. Actually, the serial measurements of these markers could allow changing treatment frequency (for example, every 3 months) and even theoretically allow removing therapy for periods in the context of optimal bone metabolism control.…”

Section: Dosing Of Btasmentioning

confidence: 99%

“…These pyridinium crosslinks result from the posttranslational modification of lysine and hydrolysine in bone and represent fragments of crosslinking amino-acid derivatives that stabilize the collagen type I fibrils in bone. 12 The crosslinked telopeptides that are released from type I collagen degradation by proteases during bone resorption generate neoepitopes (CTX-I, ICTP, NTX-I). The C-terminal telopeptide, CTX-I, as well the N-terminal telopeptide, NTX-I, when compared with ICTP, reflect different enzymatic pathways of bone breakdown, by cathepsin K or matrix metalloptoteinase-1 (MMP-1) cleavage of collagen type I, respectively.…”

Section: Biochemical Markers Of Bone Turnovermentioning

confidence: 99%

See 2 more Smart Citations

Bone remodeling markers and bone metastases: From cancer research to clinical implications

Ferreira¹,

Alho²,

Casimiro³

et al. 2015

BoneKEy Reports

View full text Add to dashboard Cite

Bone metastasis is a frequent finding in the natural history of several types of cancers. However, its anticipated risk, diagnosis and response to therapy are still challenging to assess in clinical practice. Markers of bone metabolism are biochemical by-products that provide insight into the tumor-bone interaction, with potential to enhance the clinical management of patients with bone metastases. In fact, these markers had a cornerstone role in the development of bone-targeted agents; however, its translation to routine practice is still unclear, as reflected by current international guidelines. In this review, we aimed to capture several of the research and clinical translational challenges regarding the use of bone metabolism markers that we consider relevant for future research in bone metastasis.

show abstract

Section: Prediction Of Patients' Outcomesmentioning

confidence: 99%

Section: Dosing Of Btasmentioning

confidence: 99%

Section: Biochemical Markers Of Bone Turnovermentioning

confidence: 99%

See 1 more Smart Citation

Bone remodeling markers and bone metastases: From cancer research to clinical implications

Ferreira¹,

Alho²,

Casimiro³

et al. 2015

BoneKEy Reports

View full text Add to dashboard Cite

show abstract

“…Serial measurements of bone turnover markers can be used as a guide to the frequency and dosage of bisphosphonate drug used. A study by Costa et al [15] evaluated the role of bone turnover markers for the monitoring of metastatic breast cancer patients. Of the markers studied, urinary NTX (uNTX) showed the most diagnostic accuracy and was able to predict the progression of metastatic disease most reliably.…”

Section: Bone Turnover Markersmentioning

confidence: 99%

Bisphosphonates and metastasis

Lester

Coleman

2005

Breast Cancer Online

View full text Add to dashboard Cite

IntroductionIn recent years the increasing use of adjuvant chemotherapy and endocrine therapy have resulted in a decline in breast cancer mortality despite a steady increase in incidence [1].Bone is a common site for the distant spread of breast cancer with as many as 70% of breast cancer patients having bone metastasis at post-mortem. Significant morbidity from bone metastasis may occur due to pathological fracture, hypercalcaemia of malignancy, pain and spinal cord compression [2].The bisphosphonates are potent inhibitors of osteoclast function. There are two different classes of bisphosphonates; the nitrogen containing and the non-nitrogen containing compounds. Nitrogen containing bisphosphonates include pamidronate, alendronate, risedronate, zoledronic acid and ibandronate. These drugs have the greatest affinity and potency and act through the inhibition of farnesyl diphosphate (FPP) synthase in the mevalonate pathway. Nonnitrogen containing bisphosphonates include etidronate and clodronate, with the latter working through effects on mitochondrial ATP in osteoclasts.The exact mechanisms of action remain unclear. However, animal studies with a variety of tumour models suggest that bisphosphonates may stimulate apoptosis of both the tumour cell and the osteoclast [3][4][5]. Bone turnoverBone is constantly undergoing a process of renewal known as remodelling. This process of bone resorption followed by formation is a delicate balance between two cell types, the osteoclast and the osteoblast. Control of these cell types is regulated by a combination of systemic hormones and local factors that affect the replication and differentiation of osteoblasts and osteoclasts.Growth factors, such as insulin-like growth factors (IGF-I and IGF-II), transforming growth factor-␤ (TGF-␤), fibroblast growth factors (FGFs) and plateletderived growth factor (PDGF) mainly act to increase bone formation and repair. Cytokines involved in Abstract Bone metastases frequently occur in advanced breast cancer patients and once incorporated into bone have profound effects on bone physiology. Bisphosphonates are potent inhibitors of osteoclastic function and are becoming increasingly important for the management of patients with breast cancer. They affect the ability of cancer cells to accelerate bone turnover and as a result control pain and reduce the risk of pathological fracture.Furthermore ongoing clinical trials are investigating the role of bisphosphonates as an adjuvant therapy in high-risk breast cancer patients with an aim to prevent bone metastasis.This article reviews the mechanisms of bone metastasis and will discuss present and future developments for the monitoring and treatment of metastatic bone disease.

show abstract

“…The only published results concerning NTX refer to the monitoring of patients with bone metastases from breast carcinoma, and, to the best of our knowledge, these have never been compared with the UCa/Cr ratio. 9,10 With regard to bone alkaline phosphatase, we could discuss forever the question of osteoblastic flares (which Berruti et al define as a Ͼ 15% increase in the already very high levels of total alkaline phosphatase!). However, even assuming that it can be demonstrated unequivocally, an osteoblastic flare may be related to the beginning of hormone therapy, because it is widely known that it can be caused by lutenizing hormone-releasing hormone therapy.…”

mentioning

confidence: 99%

Urinary calcium excretion in the monitoring of bone metastases from prostatic carcinoma

Berruti

Tucci

Dogliotti

et al. 2002

Cancer

View full text Add to dashboard Cite

Prospective Evaluation of the Peptide-Bound Collagen Type I Cross-Links N-Telopeptide and C-Telopeptide in Predicting Bone Metastases Status

Abstract: Urinary NTX may be a valuable bone marker to assess the antiresorptive effect of bisphosphonate therapy and to evaluate the progression of bone metastases.

Cited by 137 publications

References 16 publications

Bone remodeling markers and bone metastases: From cancer research to clinical implications

Bone remodeling markers and bone metastases: From cancer research to clinical implications

Bisphosphonates and metastasis

Urinary calcium excretion in the monitoring of bone metastases from prostatic carcinoma

Contact Info

Product

Resources

About